AI-Driven Drug Development - BullFrog AI Expands Licensing Deal With Johns Hopkins Applied Physics Laboratory
Portfolio Pulse from Nabaparna Bhattacharya
BullFrog AI Holdings (NASDAQ:BFRG) expands its worldwide license agreement with Johns Hopkins Applied Physics Laboratory (APL) for the patented technology powering its AI-driven bfLEAP platform. The platform analyzes drug development data to make life-saving therapies and treatments, streamlining data analytics and reducing development costs.
June 05, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BullFrog AI expands its license agreement with Johns Hopkins APL for the AI-driven bfLEAP platform, which streamlines drug development data analytics and reduces costs. BFRG shares are up 2.97% to $4.85.
The expanded license agreement with Johns Hopkins APL allows BullFrog AI to further develop and improve its AI-driven bfLEAP platform, which has the potential to disrupt the drug development industry. This positive news has led to an increase in BFRG's stock price by 2.97% to $4.85, indicating a positive short-term impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100